Table 3.
List of active trials
| Condition | Identifier | Status | Study Start Date | Study Completion Date | Ph | EP | Primary Objectives | Drugs |
|---|---|---|---|---|---|---|---|---|
| RAIR- DTC | NCT05660954 | not yet recruiting | April, 2023 | June, 2025 | II | 41 | Gene expression | cabozantinib |
| DTC | NCT03914300 | active, not recruiting | July 15, 2019 | January 15, 2024 | II | 27 | ORR | cabozantinib, nivolumab and ipilimumab |
| RAIR- DTC | NCT02041260 | active, not recruiting | January 2014 | May 2022 | II | 43 | AEs | cabozantinib |
| Advanced DTC (+others) | NCT04514484 | recruiting | November 4, 2020 | November 2, 2025 | I | 18 | DLTs | cabozantinib and nivolumab |
| DTC (+others) | NCT03170960 | active, not recruiting | September 5, 2017 | August 2024 | Ib | 1732 | MTD | cabozantinib and atezolizumab |
| PPGL | NCT02302833 | recruiting | February 17, 2015 | December 31, 2023 | II | 22 | ORR | cabozantinib |
| ACC | NCT03612232 | recruiting | June 4, 2019 | April 30, 2025 | II | 37 | PFS | cabozantinib |
| ACC | NCT03370718 | active, not recruiting | February 26, 2018 | February 28, 2026 | II | 18 | PFS | cabozantinib |
| NEN | NCT03375320 | recruiting | July 18, 2018 | October 1, 2025 | III | 395 | PFS | cabozantinib |
| NEC | NCT04079712 | active, not recruiting | January 14, 2020 | October 1, 2023 | II | 30 | ORR | cabozantinib, nivolumab, and ipilimumab |
| NEN | NCT04412629 | recruiting | November 24, 2020 | July 31, 2025 | II | 32 | ORR | cabozantinib |
| NEN | NCT04893785 | recruiting | June 15, 2021 | December 2024 | II | 35 | ORR | cabozantinib, temozolomide |
| NEN | NCT04427787 | recruiting | June 20, 2020 | November 2023 | II | 69 | ORR | cabozantinib, lanreotide |
| NEN | NCT05249114 | recruiting | December 28, 2022 | December 1, 2031 | Ib | 90 | MTD | cabozantinib, PRRT |
| Carcinoid Tumours | NCT04197310 | active, not recruiting | December 26, 2019 | December 26, 2023 | II | 35 | ORR | cabozantinib, nivolumab |
| NEN, PPGL, ATC, Adenocarcinoma | NCT04400474 | active, not recruiting | October 7, 2020 | March 2024 | II | 93 | ORR | cabozantinib, atezolizumab |
| NEN | NCT05048901 | recruiting | September 17, 2021 | December 31, 2025 | I/II | 49 | MTD, PFS | cabozantinib |
| NEN G3 | NCT04524208 | recruiting | March 1, 2021 | June 30, 2023 | II | 40 | DCR | cabozantinib |
| NEN G3 | NCT05289856 | recruiting | March 28, 2022 | December 1, 2025 | II | 30 | DCR | cabozantinib, avelumab |
RAIR Radioiodine-Refractory, DTC Differentiated Thyroid Carcinoma, PPGL Pheochromocytoma and Paraganglioma, ACC Adrenocortical Carcinoma, NEN Neuroendocrine Neoplasm, ATC Anaplastic Thyroid Carcinoma, NEC Neuroendocrine Carcinoma, Ph Phase, ER Enrolled Patients, DLTs Dose Limiting Toxicities, ORR Overall Response Rate, PFS Progression Free Survival, MTD Maximum Tolerated Dose, DCT Disease Control Rate, G grade